New Cancer Drugs in India: Approvals, Access & Cost
How new cancer drugs, including India's first CAR-T therapy, reach the market through CDSCO, and how NPPA's trade margin cap changed oncology pricing.
This cancer drug India overview covers how a new cancer drug actually gets to an Indian patient, what NPPA's oncology-specific price intervention changed, and what both mean for a hospital stocking or referring for cancer therapy.
How does a new cancer drug get approved for use in India?
A new cancer drug requires CDSCO marketing authorisation before it can be sold in India, following clinical trial data reviewed under the Drugs and Cosmetics Act framework, the same core pathway every new drug follows regardless of therapeutic area. Oncology drugs, particularly biologics and cell therapies, additionally involve India's biosimilar and cell-and-gene-therapy specific regulatory guidance where the product doesn't fit a conventional small-molecule pathway.
NexCAR19's approval illustrates this: a genetically engineered cell therapy targeting CD19 for relapsed or refractory B-cell lymphomas and leukaemia, it required a dedicated approval pathway distinct from a standard chemotherapy or targeted small-molecule drug, reflecting the novel manufacturing and delivery process cell therapies involve.
What makes NexCAR19 significant beyond being "a new drug"?
NexCAR19 is India's first indigenously developed CAR-T cell therapy, built and manufactured domestically rather than imported, which is the direct reason its price sits at roughly a tenth of comparable therapies available in the US and Europe. Its pivotal trial data showed close to a 70% overall response rate across 60 patients with relapsed or refractory B-cell lymphomas and leukaemia.
Domestic manufacturing capacity for a therapy this complex is itself the more durable story than the price point alone, since it establishes a manufacturing and regulatory template India can apply to future cell and gene therapies rather than depending entirely on imported product for this therapy class.
What did NPPA's 2019 trade margin cap actually change for cancer drug pricing?
NPPA capped trade margins on 42 non-scheduled anti-cancer drugs at 30% of MRP in February 2019, using its emergency powers under Paragraph 19 of the Drugs (Prices Control) Order 2013 rather than the standard scheduled-formulation mechanism. This covered 72 formulations across 355 brands.
The intervention cut MRPs by up to 85% for around 105 brands, with the government's own estimate putting patient savings at roughly ₹200 crore annually. This was a margin cap on the trade channel, not a ceiling price on the drug itself, which is a different regulatory tool than the one NPPA uses for scheduled formulations like levothyroxine or inhaled steroids.
Why did NPPA use trade margin capping instead of its usual ceiling-price mechanism for cancer drugs?
Cancer drugs, particularly the 42 targeted in 2019, were largely non-scheduled formulations, meaning they sat outside Schedule I of the DPCO and had no existing ceiling price NPPA could simply enforce. The trade margin mechanism let NPPA intervene on high markup between manufacturer price and patient-facing MRP without going through the longer process of adding each drug to the schedule.
This distinction matters for anyone tracking oncology drug pricing going forward: a new cancer drug entering the Indian market today is not automatically price-controlled the way a scheduled essential medicine is, and further trade-margin interventions of this kind remain a live regulatory tool rather than a one-time 2019 event.
Does India's oncology drug access extend to the newest global therapies immediately?
Not automatically. A drug's global approval, by the FDA or EMA for instance, does not itself grant Indian market access; CDSCO approval, based on data reviewed independently or through applicable bridging requirements, is a separate step that can lag a global approval by months or years depending on the sponsor's India filing timeline.
This gap is precisely why domestically developed therapies like NexCAR19 carry outsized significance for cancer drug India access: they close the availability and affordability gap directly rather than depending on when and whether an international originator chooses to file and price for the Indian market.
What does this mean for a hospital's oncology pharmacy and referral stocking?
Oncology drugs, from established chemotherapy agents through newer targeted and cell therapies, are high-value, low-margin-for-error prescriptions where a hospital's in-house pharmacy reliability directly affects whether a patient continues treatment at that facility or is referred, and their prescription revenue, elsewhere. A cancer patient sent out for a single unavailable formulation is a patient a competing facility can capture for the remainder of a treatment course.
Reliable in-house stocking, aligned to the NPPA-regulated and non-regulated formulation mix a hospital's oncology or medicine department actually prescribes, is the operational foundation for keeping that treatment relationship inside the hospital. Medyzen's managed hospital pharmacy services piece covers how that stocking model is built, and the prescription leakage piece covers what a single referred-out oncology patient costs a hospital across a full treatment course rather than one prescription. Our biosimilar guide covers a related affordability lever for high-cost oncology and chronic biologic therapies.
Sources
- 1NPPA plays crucial role in making Cancer Drugs affordable — Press Information Bureau, Government of India
- 2Significant Reduction in Cancer Drug Prices due to Trade Margin Capping — Press Information Bureau, Government of India
- 3India's first domestic CAR-T approval — Cell & Gene, industry reporting on ImmunoACT's CDSCO approval
- 4India puts 42 non-scheduled cancer drugs under price control — Mondaq, legal and regulatory analysis of the NPPA order
- 5National Pharmaceutical Pricing Authority — Ministry of Chemicals and Fertilizers, Government of India
This article is for informational purposes and is not a substitute for professional medical advice. Approval status and pricing figures are drawn from cited government and industry sources current as of the date checked and change as new drugs are approved. Consult a treating oncologist for individual treatment decisions.
FAQ
Frequently asked questions
NexCAR19, developed by IIT Bombay-incubated ImmunoACT and approved by CDSCO, targets relapsed or refractory B-cell lymphomas and leukaemia and is priced at roughly a tenth of comparable global CAR-T therapies.
Partially. Some formulations are NPPA-scheduled with a ceiling price; many others were brought under a 30% trade margin cap in 2019 rather than a full price ceiling, and newly launched cancer drugs are not automatically price-controlled.
The government estimated roughly ₹200 crore in annual patient savings, with MRPs cut by up to 85% for around 105 brands across 72 formulations covered by the trade margin cap.
No. It requires separate CDSCO marketing authorisation, which can lag international approval by months or years depending on when the manufacturer files for the Indian market.
It builds India's regulatory and manufacturing template for future cell and gene therapies, reducing dependence on imported product and the pricing and access lag that comes with it.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.